Periodic Reporting for period 1 - TIR-C (NEXT GENERATION TOPICAL MEDICATION TO TREAT IMMUNE RESPONSES IN ATOPIC DERMATITIS – THE MOST COMMON CAUSE OF ECZEMA)
Periodo di rendicontazione: 2019-12-01 al 2020-05-31
TIRmed Pharma AB has developed a non-steroid cream that relieves inflammation and itch in AD. Our TIR-C cream works through an entirely novel mechanism of action. The therapy has been developed with the largest patient group in mind - children. TIR-C has the potential to become a blockbuster in AD management as it has an excellent safety profile. Moreover, is affordable, easy to self-apply (water-based), doesn’t interfere with vital immune defences and has the potential to prevent disease escalation.
A health economic survey performed in this study, based on interviews with KOLs and clinicians, allowed us to validate acceptable pricing levels and analyse the willingness-to-pay. We have further strengthened our relationships with clinical, distribution, and pharma partners. TIRmed plans to integrate their expertise into the production process, optimising undertaken activities and expenditures.
The overall results indicate, that there is a substantial need for developing and delivering a safe, efficacious and cost-efficient treatment option for AD. The study allowed us to develop a business plan. enabling reaching our financial and commercialisation targets, aligned with the overall business development strategy of the company.